{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005063","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.961402+00:00","generated_at":"2026-06-18T21:47:35.212500+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220","bullets":["Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.","Q4 2022 revenue $44.4M from collaborations; R&D expense $87.2M, G&A $21.6M.","Janssen collaboration terminated effective Apr 3, 2023; all programs discontinued.","Restructuring reduces headcount to ~220; expects $12-16M severance charges in Q1 2023.","IND planned mid-2023 for FT522 in B-cell lymphoma; FT825/ONO-8250 IND expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005063","json":"https://secwatch.observer/filing/0000950170-23-005063.json","markdown":"https://secwatch.observer/filing/0000950170-23-005063.md","text":"https://secwatch.observer/filing/0000950170-23-005063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/0000950170-23-005063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/fate-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:47:35.212500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff7a6e697f70dec63e08c38b9022ab9f75fcc567","claim":"FATE THERAPEUTICS INC reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023005063/0000950170-23-005063-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}